80.9902.57% ( +2.030 )
Closed: Oct 5, 16:00:00 (EDT)Current ValuationThe current P/E ratio is 28.18, below the reasonable range, cheaper than 97.93% of the time in the past 5 years, and the industry ranks 28/174, the industry Median -0.98.
28.18xP/E
$80.99Stock price
$2.87Earnings per share
28.18xP/E
Stock price$80.99Earnings per share$2.87
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 45.00x
- Typical range
- 37.34x–52.72x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
012243648
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
MDTUSMedtronic | 21.51x | 25.38% | $112.53B |
SYKUSStryker | 29.34x | 53.09% | $109.40B |
BSXUSBoston Scientific | 16.72x | 36.31% | $61.45B |
RMDUSResmed | 21.10x | 11.53% | $32.15B |
RYLPFUSKoninklijke Philips N.V. | 17.45x | -- | $22.56B |
PHGUSKoninklijke Philips Elect | 18.07x | 14.78% | $23.37B |
TRUMYUSTerumo | 20.27x | -- | $21.30B |
STEUSSteris | 25.56x | 17.10% | $20.58B |
ZBHUSZimmer Biomet | 21.65x | 37.01% | $17.47B |
SNNUSSmith and Nephew | 17.83x | 42.74% | $11.32B |
GMEDUSGlobus Medical Inc | 19.20x | 6.02% | $10.28B |
PODDUSInsulet | 25.06x | 76.03% | $9.41B |
SSMXYUSSysmex | 27.75x | -- | $7.02B |
LIVNUSLivanova | 22.33x | 189.82% | $4.21B |
TMDXUSTransMedics | 18.97x | 71.90% | $2.88B |
INSPUSInspire Medical | 15.15x | 100.86% | $2.05B |
LMATUSLemaitre Vascular | 28.18x | 13.99% | $1.85B |
CNMDUSConmed | 25.09x | 156.95% | $1.42B |
TCMDUSTactile | 20.47x | 36.59% | $509.00M |
BWAYUSBrainsway | 25.37x | 70.37% | $239.53M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
